share_log

DEF 14A: Definitive information statements

DEF 14A: Definitive information statements

DEF 14A：股东委托书决议
美股SEC公告 ·  09/18 17:03

Moomoo AI 已提取核心信息

Heart Test Laboratories, Inc. (HeartSciences) has filed its definitive proxy statement with the U.S. Securities and Exchange Commission (SEC) on September 18, 2024, for its upcoming Annual Meeting of Shareholders scheduled for November 7, 2024. The meeting will be held virtually via a live audio webcast. Shareholders will vote on the ratification of Haskell & White LLP as the company's independent registered public accounting firm for the fiscal year ending April 30, 2025, and on the approval of an adjournment of the Annual Meeting if necessary to solicit additional proxies. The company did not hold a 2023 Annual Meeting of Shareholders, and as such, is soliciting approval for both its Class I and Class II director nominees collectively. The sole Class III director nominee's term expires at the 2025 Annual Meeting, and therefore, no approval for this position is sought at the current meeting. Shareholders as of the record date, September 16, 2024, are entitled to vote, and the company has provided various methods for shareholders to submit their proxies.
Heart Test Laboratories, Inc. (HeartSciences) has filed its definitive proxy statement with the U.S. Securities and Exchange Commission (SEC) on September 18, 2024, for its upcoming Annual Meeting of Shareholders scheduled for November 7, 2024. The meeting will be held virtually via a live audio webcast. Shareholders will vote on the ratification of Haskell & White LLP as the company's independent registered public accounting firm for the fiscal year ending April 30, 2025, and on the approval of an adjournment of the Annual Meeting if necessary to solicit additional proxies. The company did not hold a 2023 Annual Meeting of Shareholders, and as such, is soliciting approval for both its Class I and Class II director nominees collectively. The sole Class III director nominee's term expires at the 2025 Annual Meeting, and therefore, no approval for this position is sought at the current meeting. Shareholders as of the record date, September 16, 2024, are entitled to vote, and the company has provided various methods for shareholders to submit their proxies.
HeartSciences（心脏测试实验室）于2024年9月18日向美国证券交易委员会（SEC）提交了其明确的代理声明，计划于2024年11月7日举行的股东年会上进行讨论。会议将通过现场音频网络直播的形式进行。股东们将就Haskell & White LLP公司作为该公司独立注册的公共会计师事务所对2025年4月30日结束的财政年度进行批准投票，并对如果有必要为招募其他代理提供的年会延期进行批准投票。该公司没有举行2023年的股东年会，因此，现在正在征求对其I类和II类董事提名的批准。唯一的III类董事提名在2025年的股东年会上任期届满，因此，当前会议不需要对该职位进行批准。截至记录日2024年9月16日，股东们有权投票，公司已经提供了各种方式供股东们提交代理。
HeartSciences（心脏测试实验室）于2024年9月18日向美国证券交易委员会（SEC）提交了其明确的代理声明，计划于2024年11月7日举行的股东年会上进行讨论。会议将通过现场音频网络直播的形式进行。股东们将就Haskell & White LLP公司作为该公司独立注册的公共会计师事务所对2025年4月30日结束的财政年度进行批准投票，并对如果有必要为招募其他代理提供的年会延期进行批准投票。该公司没有举行2023年的股东年会，因此，现在正在征求对其I类和II类董事提名的批准。唯一的III类董事提名在2025年的股东年会上任期届满，因此，当前会议不需要对该职位进行批准。截至记录日2024年9月16日，股东们有权投票，公司已经提供了各种方式供股东们提交代理。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间